Viktor Rognås
Research Assistant at Institutionen för farmaci; Farmakokinetik och Farmakodynamik
- E-mail:
- viktor.rognas@farmaci.uu.se
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
752 37 Uppsala - Postal address:
- Box 580
751 23 UPPSALA
PhD student at Uppsala antibiotikacentrum
- Visiting address:
- BMC, SciLifeLab Entrance C11, Room E10:4210
752 37 Uppsala - Postal address:
- BMC, Box 582, Husargatan 3
751 23 Uppsala
Download contact information for Viktor Rognås at Uppsala antibiotikacentrum
- CV:
- Download CV
- ORCID:
- 0000-0002-7837-2467
More information is available to staff who log in.
Keywords
- antibacterial development
- antibiotic resistance
- pharmacometrics
Biography
Hello! I'm currently working on my Ph.D. within Uppsala Antibiotic Center. Back in 2017, I got my master's in Chemical Engineering from Uppsala University. At the same time, I explored the world of business and got a diploma from the School of Entrepreneurship.
But it's not all about studies! I'm also part of the team working on Pharmpy, a software project for pharmacometrics. You can see what we're up to on GitHub.
Want to know more? Check out my personal website
Research
I'm diving deep into the complex world of antibiotic drug development, specifically focusing on colistin, a powerful antibiotic. Inspired by the work of Dr John Rex and others in 2013, my goal is to make antibiotic drug development more feasible by designing efficient clinical trials.
I'm developing methods to analyze trial data more effectively, aiming to reduce the number of patients needed in studies, and incorporating pre-existing data to enhance our understanding of treatments for specific groups of patients.
Through a series of projects, I'm analyzing colistin's effects on critically ill patients, including its impact on kidney function and its efficacy against resistant bacteria. I'm also keen on utilizing modern, adaptive study designs to maximize the efficiency of clinical trials for antibiotic treatments, ultimately aiming to facilitate the development of new, effective drug combinations.
Media
Combining colistin and meropenem in critically ill patients
Part of the Uppsala Antibiotic Center (UAC) seminar series UAC: https://uac.uu.se
https://www.youtube.com/watch?v=jrnQOBv5OPQ
Publications
Selection of publications
- Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms (2020)
- Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria (2020)
Recent publications
- Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms (2020)
- Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria (2020)
All publications
Articles
- Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms (2020)
- Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria (2020)